Neimeth International Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Neimeth International Pharmaceuticals has a total shareholder equity of NGN1.5B and total debt of NGN4.2B, which brings its debt-to-equity ratio to 269.6%. Its total assets and total liabilities are NGN9.0B and NGN7.5B respectively.
Key information
269.6%
Debt to equity ratio
₦4.17b
Debt
Interest coverage ratio | n/a |
Cash | ₦2.00b |
Equity | ₦1.55b |
Total liabilities | ₦7.47b |
Total assets | ₦9.02b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: NEIMETH's short term assets (NGN5.2B) do not cover its short term liabilities (NGN7.0B).
Long Term Liabilities: NEIMETH's short term assets (NGN5.2B) exceed its long term liabilities (NGN473.8M).
Debt to Equity History and Analysis
Debt Level: NEIMETH's net debt to equity ratio (140.1%) is considered high.
Reducing Debt: NEIMETH's debt to equity ratio has increased from 98.8% to 269.6% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NEIMETH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NEIMETH has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 58.1% each year.